| acute myocardial infarction | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| USIM, 1991 | vs control | | | |
| Trial | Treatments | Patients | Method |
|---|
| USIM, 1991 | urokinase bolus dose of 1 million U repeated after 60 minutes plus heparin (n=1128) vs. control (heparin alone) (n=1073) | patients with acute myocardial infarction within 4 hours of the onset of pain | open Parallel groups Sample size: 1128/1073 Primary endpoint: FU duration: in hospital |
|
| pulmonary embolism | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| UPET, 1973 | vs placebo | | | All cause death 0.82 [0.29; 2.32] major bleeding 1.90 [0.99; 3.66] minor bleeding 1.43 [0.68; 2.98] recurrence of pulmonary embolism 0.76 [0.38; 1.52] | | Marini, 1988 | vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| UPET, 1973 | urokinase 2,000-U/lb bolus, then 2,000 U/lb per h IV for 12 h and heparin (n=82) vs. placebo + Heparin (a loading dose of 75 U/pound, then 10 U/pound/hr for 12 hr infusion, then heparin for a minimum of 5 days, followed by heparin or warfarin therapy for a total of 14 days) (n=78) | patients with pulmonary embolism | double blind Parallel groups Sample size: 82/78 Primary endpoint: FU duration: <14 days | | Marini, 1988 | urokinase 800,000 U/d IV for 72 h, UK 3,300,000 U IV for 12 h and heparin (n=20) vs. heparin (n=10) | patients with pulmonary embolism | open Sample size: 20/10 Primary endpoint: FU duration: 7 days |
|
| venous thrombosis | All results are NS for efficacy inferior to no fibrinolysis in terms of Complete clot lysis (late) in Schweizer (urokinase), 1998 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Kiil, 1981 | vs no fibrinolysis | | | Mortality (early) 0.00 [0.00; NaN] Bleeding (early) 0.61 [0.18; 2.06] Any improvement in venous patency (early) 0.73 [0.05; 9.97] Stroke/intracerebral bleeding (eraly) NaN [NaN; NaN] | | Schweizer (urokinase), 1998 | vs no fibrinolysis | | Complete clot lysis (late) 2.13 [1.17; 3.86] | Mortality (early) ∞ [NaN; ∞] Post-thrombotic syndrome (late) 0.65 [0.40; 1.04] Leg ulceration (late) 1.00 [0.07; 15.00] Stroke/intracerebral bleeding (eraly) NaN [NaN; NaN] | | Schweizer (local urokinase), 2000 | vs no fibrinolysis | | | | | Schweizer (systemic urokinase), 2000 | vs no fibrinolysis | | | |
| Trial | Treatments | Patients | Method |
|---|
| Kiil, 1981 | urokinase 200,000 U IV over 24 hours. After 18 hours, heparin loading dose of 15,000 units
then 40,000 U/day for 5 days (+placebo) (n=20) vs. heparin 40,000 U/day IV for 6 days (+placebo) (n=0) | patients with venographically confirmed DVT duration < 72 hours | Double blind Parallel groups Sample size: 20/0 Primary endpoint: FU duration: | | Schweizer (urokinase), 1998 | Urokinase 100,000 IU/hr IV into pedal vein continuously for 7 days. Heparin IV for 7 days. Plasminogen
monitored. Warfarin from day 7 to 12 monthsd=132 (n=-9) vs. heparin IV, adjusted for 7 days (n=-9) | patients with venographically confirmed DVT of leg duration < 7 days | single blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: | | Schweizer (local urokinase), 2000 | Local urokinase 100,000 IU/day infused continuously. Fibrinogen and plasminogen monitored. Heparin IV given concomitantly (n=-9) vs. heparin IV, adjusted (n=-9) | patients with thrombosis of popliteal or more proximal veins confirmed by venogram at more than one level of duration < 9 days | single blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: | | Schweizer (systemic urokinase), 2000 | Systemic urokinase 5,000,000 IU/day over 4 hours for up to 7 days. IV heparin given concomitantly (n=-9) vs. heparin IV, adjusted (n=-9) | patients with thrombosis of popliteal or more proximal veins confirmed by venogram at more than one level of duration < 9 days | single blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
|
